BioTech

STAT Plus: Blueprint and Ipsen to work collectively on remedy for ultra-rare genetic dysfunction

Blueprint Medicines will obtain $25 million to collaborate with the French drug maker Ipsen on a possible medical remedy that the Cambridge, Mass., biotech has developed for an ultra-rare genetic illness.

The licensing deal marks the fourth collaboration between Blueprint — based in 2008 — and one other main drug maker in lower than 5 years.

Proceed to STAT Plus to learn the total story…

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker